GSK•benzinga•November 5, 2024 at 01:12 PM

GSK's AREXVY Vaccine Receives Expanded Approval In Canada For Adults Aged 50-59 At Increased Risk Of RSV, Offering Enhanced Protection Ahead Of Peak Season; Clinical Trials Ongoing For Adults 18-49

No summary available.

Read the full article from the original source for complete details and context.

Article published on November 5, 2024 by benzinga